Navigation Links
Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study

Phase III trial planned
Abstracts: 2000, 2002

CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of a Phase I/IIa study presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago demonstrate the clinical activity of cilengitide in patients with newly diagnosed glioblastoma – a particularly aggressive form of brain tumor. Cilengitide is a highly selective integrin inhibitor targeting the tumor and its vasculature.

Fifty-two patients with newly diagnosed glioblastoma were treated with cilengitide, combined with a standard regimen of radiotherapy and temozolomide following tumor resection or biopsy. The study reached the predefined primary endpoint with 69% of patients being alive and progression free at six months, and showed a median progression free survival (PFS) of 8.1 months. In a defined patient subgroup with the methylated MGMT gene promoter in the tumor tissue, 91% of patients had six months PFS and the median has not yet been reached. These results are encouraging when compared to the historical control of the EORTC-NCIC phase III trial [overall population: 54% 6 months PFS, median PFS of 6.9 months;(1) methylated MGMT gene promoter subgroup: 69% PFS and 10.3 months median PFS].(2)

Lead investigator Dr. Roger Stupp of the University of Lausanne Hospital in Switzerland, commented: “We are excited by these findings. They demonstrate the potential of cilengitide to make a real difference to the outcome of patients with this aggressive type of brain cancer, where currently available treatment options are limited and prognosis is poor. We look forward to learning more about the benefits of this promising agent in larger patient populations.”

Also presented at ASCO was a Phase IIa randomized multicenter trial, examining two dosing levels of cilengitide monotherapy (500mg and 2000mg) in 81 patients with recurrent gliobl
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
11. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
Post Your Comments:
(Date:7/3/2015)... July 3, 2015 Redwood Pharma ... Technologies Co., Ltd., operating in both the US and ... proprietary IntelliGel ® supramolecular hydrogel technology in its ... other ophthalmic therapies. The Broda technology offers many unique ... a free-forming liquid and with low concentrations of polymer ...
(Date:7/2/2015)... , July 2, 2015 /PRNewswire/ - ESSA Pharma Inc. ... common shares have been approved for listing and trading on ... ESSA will begin trading on NASDAQ on July 9, ... Venture Exchange under the symbol "EPI". As a ... NASDAQ, each of the Company,s outstanding special warrants issued on ...
(Date:7/2/2015)... NYACK, N.Y. , July 2, 2015  Before you ... plan ahead so you can stay safe and healthy. Take ... plants #summersafety. Infographic http://nyackhospital.org/summersafety Protect Your ... rays from the sun can increase your risk of skin ... the shade as much as possible, especially during midday hours. ...
Breaking Medicine Technology:Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3
... SurgLine International, Inc. (SGLN.PK) Thomas Toland, ... the company has successfully completed its first sports medicine ... in the state of Indiana. The case involved specialized ... the competition. Toland was quoted as ...
... YORK, April 18, 2012 ... coverage on Pacira Pharmaceuticals Inc., ... target $18.00. ... a member of the Financial ...
Cached Medicine Technology:SurgLine International, Inc. Update On New Revenues 2
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich , ... held from March 4th - 6th, the 2016 (a previous announcement had stated the ... to take participants from the basic training and fundamentals of nasal surgery through the ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, ... retained to lead a national chief nursing officer recruitment for Jane ... in the healthcare industry, B. E. Smith has recently placed more than 1,000 ...
(Date:7/3/2015)... CT (PRWEB) , ... July 03, 2015 , ... Smoothies ... home is a good blender and easily accessible, quality ingredients. Aurora Natural is proud ... smoothie for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is the new ... the largest network of independent freestanding emergency rooms in the United States. , “We ... Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency Room, Dr. James ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... selfie sticks are great for documenting memories. , Almost every smartphone has an incredibly ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... ... improved longevity , ... YORK (PRWEB) March 30, 2010 -- CogniFit™, Inc., a leading maker of Brain Fitness ... longevity, author and speaker, is now an official spokesperson for CogniFit. Berg, who is ...
... ... , ... (PRWEB) March 30, 2010 -- Canadian Web Hosting ( http://www.canadianwebhosting.com ), a leading provider ... for their popular affiliate program. The immediate increase from $35 to $60 for sales ...
... Medicine found that women with serum uric acid levels over ... than men. This study, the first to examine the ... also evaluated purported risk factors for gout and found that ... be among leading contributors for women. Results of this ...
... others much less severe is largely a mystery. It ... be attributed to differences in how individuals respond to ... for General Microbiology,s spring meeting in Edinburgh today, describes ... allow treatments to be tailored to individuals. This approach ...
... patients are also at high risk for coverage gap, ... Among elderly Americans, women and those with diabetes and ... Medicare Part D drug plan "doughnut hole," the coverage ... annual coverage limit but hasn,t spent enough on drugs ...
... very low levels of violence between their parents, they ... new research suggests. A study by psychologists at ... witness violence between their mother and her intimate partner ... violence as threatening. The research highlights the importance ...
Cached Medicine News:Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 3Health News:Canadian Web Hosting Increases Affiliate Incentive 2Health News:Obesity, hypertension, alcohol and diuretic use -- gout risk factors for women 2Health News:Personalizing medicine to prevent pandemics 2Health News:Women, Diabetics Fall Fast Into Medicare 'Doughnut Hole' 2Health News:Children's sense of threat from parental fighting determines trauma symptoms 2
... cholangiography and bile stone ... lumen catheter design allows ... and wire basket placement ... sterile in peel-open packages. ...
... biopsy with the MAMMOTOME® HH ... minimally invasive procedure using ultrasound ... computer-generated images to locate breast ... pinpoint and map the area ...
... a more occlusive wrap than VICRYL knitted ... transudate must be contained. Predictable absorption. Polyglactin ... nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin 910) woven ... copolymer of glycolide and lactide, derived respectively ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: